Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Atara Biotherapeutics ( (ATRA) ) has shared an update.
On May 14, 2025, Atara Biotherapeutics announced the appointment of James Huang and Nachi Subramanian to its Board of Directors following a direct offering of shares and warrants to institutional investors, expected to close on May 16, 2025. The company aims to extend its cash runway through the first quarter of 2026 with the $16 million proceeds, supporting its ongoing activities for potential BLA approval. Atara has transferred manufacturing responsibilities to Pierre Fabre Laboratories, significantly reducing operating expenses, and has paused its CAR T programs while undergoing organizational restructuring, including a 30% workforce reduction.
The most recent analyst rating on (ATRA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.
Spark’s Take on ATRA Stock
According to Spark, TipRanks’ AI Analyst, ATRA is a Underperform.
Atara Biotherapeutics faces significant financial and operational challenges despite strong revenue growth. High liabilities, negative cash flow, and a poor valuation dampen the stock’s outlook. The FDA’s recent positive decision offers some hope, but strategic hurdles and financial instability weigh heavily on the overall score.
To see Spark’s full report on ATRA stock, click here.
More about Atara Biotherapeutics
Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leverages its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases.
Average Trading Volume: 57,373
Technical Sentiment Signal: Sell
Current Market Cap: $39.82M
For detailed information about ATRA stock, go to TipRanks’ Stock Analysis page.